Printer Friendly

BD Diagnostics, Biodiversity to collaborate in developing diagnostic menu for patients to monitor infections in immunocompromised patients.

BD Diagnostics, a segment of Becton, Dickenson and Biodiversity SpA, a private biotech company, announced they have developed a regional collaboration to develop and commercialize a comprehensive molecular diagnostic menu for immunocompromised patients on the BDMAX System.

The companies said the portfolio will be designed to improve monitoring of infections in transplant patients. Assays developed under the collaboration of the BDMAX System can expand testing capabilities for molecular laboratories with the ability to run many different assays and samples simultaneously, which can lead to faster testing results and potentially earlier diagnosis for patients.

For more information go to: or
COPYRIGHT 2011 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Transplant News
Date:Aug 1, 2011
Previous Article:FDA panel recommends approval of Edwards transcatheter heart valve for certain inoperable patients.
Next Article:Canadian Blood Services calls for major changes in country's organ donation system.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters